# US 12,215,165 B2 · Fc variants with altered binding to FcRn

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,215,165 B2
- Document ID: US12215165B2
- Status: Granted
- Kind: B2
- Application number: 17/549,706
- Filed: 2021-12-13
- Published: 2022-04-14
- Granted: 2025-02-04
- Earliest claimed: 2004-11-12
- Assignees: Xencor, Inc.
- Applicants: Xencor, Inc.
- Inventors: Aaron Keith Chamberlain; John R. Desjarlais; Sher Bahadur Karki; Gregory Alan Lazar; Jost Vielmetter; Sean C. Yoder
- Web page: https://patentgrep.com/patent/US12215165B2

## CPC

- C07K 16/32: against translation products of oncogenes
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C07K 16/2893: {against CD52}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/526: CH3 domain
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/72: Increased effector function due to an Fc-modification
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.

## Claims

### Claim 1

A composition comprising an Fc variant of a wildtype human IgG Fc polypeptide, wherein said Fc variant comprises a serine residue at position 434, and wherein numbering is according to EU numbering.

### Claim 2

A composition comprising a variant Fc domain as compared to a wildtype human IgG Fc domain, wherein said variant Fc domain comprises a serine residue at position 434, and wherein numbering is according to EU numbering.

### Claim 3

A polypeptide comprising an Fc variant of a wildtype human IgG1 Fc polypeptide wherein said Fc variant comprises a serine residue at position 434, and wherein numbering is according to EU numbering.

### Claim 4

A composition comprising an Fc variant polypeptide, wherein the Fc variant polypeptide is encoded by a nucleic acid encoding a variant of a wildtype human IgG Fc polypeptide, wherein said Fc variant comprises a serine residue at position 434, and wherein numbering is according to EU numbering.

### Claim 5

A polypeptide encoded by a nucleic acid encoding a polypeptide comprising an Fc variant of a wildtype human IgG Fc polypeptide wherein said Fc variant comprises a serine residue at position 434, and wherein numbering is according to EU numbering.

### Claim 6

A protein comprising an Fc variant of a wildtype human IgG Fc polypeptide, wherein said Fc variant comprises a serine residue at position 434, and wherein numbering is according to EU numbering.